Skip to main content

Table 1 Patient characteristics

From: Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results

Number of patients

144

Age [years old]

 Median [range]

62 [30, 88]

 Mean ± SD

60 ± 11

Breast laterality

 Left

71 (49.3 %)

 Right

69 (47.9 %)

 Bilateral

4 (2.8 %)

Performance Status

 0

134 (93.1 %)

 1

10 (6.9 %)

 2

0

 Unknown

0

Histology

 Ductal infiltrating ca.

123 (85.4 %)

 Lobular infiltrating ca.

14 (9.7 %)

 Other

5 (3.5 %)

 DCIS

0

 Unknown

2 (1.4 %)

Grading

 G1

16 (11.1 %)

 G2

102 (70.8 %)

 G3

22 (15.3 %)

 Unknown

4 (2.8 %)

ER

 ER = 0

6 (4.2 %)

 ER > 5

135 (93.8 %)

 Unknown

3 (2.1 %)

PgR

 PgR = 0

13 (9.0 %)

 PgR > 5

128 (88.9 %)

 Unknown

3 (2.1 %)

KI67

 KI67 ≤ 20

103 (71.5 %)

 KI67 > 20

36 (25.0 %)

 Unknown

5 (3.5 %)

cerbB2

 Negative

114 (79.2 %)

 Positive

19 (13.2 %)

 Unknown

11 (7.6 %)

Surgical margins

 Negative

128 (88.9 %)

 Close

4 (2.8 %)

 Positive

1 (0.7 %)

 Unknown

11 (7.6 %)

Lesion diameter

  ≤ 1 cm

39 (27.1 %)

 Between 1 and 2 cm

68 (47.2 %)

  ≥ 2 cm

25 (17.4 %)

 Unknown

12 (8.3 %)

pT

 1

1 (0.7 %)

 1a

4 (2.8 %)

 1b

36 (25.0 %)

 1c

77 (53.5 %)

 1mic

2 (1.4 %)

 2

23 (16.0 %)

 X

0

 is

0

 Unknown

1 (0.7 %)

pN

 0

122 (84.7 %)

 1a

12 (8.3 %)

 1sn

5 (3.5 %)

 N1(mi)

1 (0.7 %)

 X

4 (2.8 %)

 Unknown

0

Chemotherapy

 Yes

21 (14.6 %)

 No

123 (85.4 %)

Hormonotherapy

 Yes

120 (83.3 %)

 No

24 (16.7 %)